Coformulated quavonlimab and pembrolizumab (pembro) in combination with lenvatinib (lenva) as first-line (1L) therapy for patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 2 KEYSTEP-004 study.

被引：0
|
作者：
Rimassa, Lorenza
Li, Daneng
Ikeda, Masafumi
Yarchoan, Mark
Ryoo, Baek-Yeol
Kossler, Thibaud
Lim, Ho-Yeong
Kwiatkowski, Mariusz
Chang, Ting-Tsung
Kim, Jee Hyun
Casadei-Gardini, Andrea
Kudo, Masatoshi
Ren, Zhenggang
Calvo, Maria Varela
Llovet, Josep M.
Zhang, Yayan
Hatogai, Ken
Siegel, Abby B.
Cheng, Ann-Lii
机构：
[1] Humanitas Univ, IRCCS Humanitas Res Hosp Rozzano, Pieve Emanuele & Humanitas Canc Ctr, Dept Med Sci, Milan, Italy
[2] City Hope Natl Comprehens Canc Ctr, Duarte, CA USA
[3] Natl Canc Ctr Hosp East, Kashiwa, Japan
[4] Johns Hopkins Univ, Baltimore, MD USA
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[6] Geneva Univ Hosp, Geneva, Switzerland
[7] Samsung Med Ctr, Seoul, South Korea
[8] Szpital Wojewodzki Mikolaja Kopernika Koszalinie, Oddzial Dzienny Chemioterapii, Koszalin, Poland
[9] Natl Cheng Kung Univ Hosp, Tainan, Taiwan
[10] Seoul Natl Univ, Bundang Hosp, Coll Med, Seongnam, South Korea
[11] San Raffaele Res Hosp, Milan, Italy
[12] Kindai Univ, Fac Med, Osaka, Japan
[13] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[14] Hosp Univ Cent Asturias, Oviedo, Spain
[15] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Liver Dis, New York, NY USA
[16] Merck & Co Inc, Rahway, NJ USA
[17] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[18] Natl Taiwan Univ Hosp, Taipei, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
283-424-425; 613-135-244-3829-325; 261-492-2769; 298-145-222-184-1022-9124; 613-3267-3650-6749; 613-615-646-2548-6283; 613-615-646-3281; 261-492-199-2823; 6; 5; 3; 2; 242; 28; 4; 1;
D O I：
10.1200/JCO.2024.42.3_suppl.484
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：484 / 484
页数：1
相关论文
共 50 条
  • [21] A phase Ib study of the PD-1 antagonist CS1003 plus lenvatinib (LEN) in Chinese patients (pts) with the first-line (1L) unresectable hepatocellular carcinoma (uHCC)
    Shen, L.
    Zhang, Y.
    Guo, Y.
    Li, W.
    Gong, J. F.
    Ma, Z.
    Peng, W.
    Wang, N.
    Ni, J.
    Qi, Q.
    Ma, Y.
    Qin, Z.
    Tse, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S690 - S691
  • [22] Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study
    Yang, J. C-H.
    Luft, A.
    De la Mora Jimenez, E.
    Lee, J. S.
    Koralewski, P.
    Karadurmus, N.
    Sugawara, S.
    Livi, L.
    Basappa, N. S.
    Quantin, X.
    Dudnik, J.
    Moran Ortiz, D.
    Mekhail, T.
    Okpara, C. E.
    Zimmer, Z.
    Samkari, A.
    Bhagwati, N.
    Csoszi, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S1429 - S1430
  • [23] Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) plus lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)
    Albiges, L.
    Gurney, H. P.
    Atduev, V.
    Suarez, C.
    Climent Duran, M. A.
    Pook, D.
    Tomczak, P.
    Barthelemy, P.
    Lee, J-L.
    Nalbandian, T.
    Stus, V.
    Ferguson, T.
    Wiechno, P.
    Gokmen, E.
    Lacombe, L.
    Gedye, C.
    Perini, R.
    Sharma, M.
    Li, C.
    Lee, C-H.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1204 - S1204
  • [24] Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS)
    Kudo, Masatoshi
    Finn, Richard S.
    Meyer, Tim
    Boisserie, Frederic
    Li, Songzi
    Chen, Yaxi
    Abdrashitov, Ramil
    Zhu, Andrew X.
    Vogel, Arndt
    Qin, Shukui
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Randomized, open-label, 3-arm phase III study comparing MK-1308A+lenvatinib and pembrolizumab (pembro) plus belzutifan plus lenvatinib versus pembro plus lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC)
    Rini, B. I.
    Plimack, E. R.
    Powles, T. B.
    Voss, M. H.
    Gurney, H. P.
    Silverman, R.
    Perini, R.
    Rodriguez-Lopez, K.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2021, 32 : S722 - S723
  • [26] Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP-002 study.
    Kudo, Masatoshi
    Finn, Richard S.
    Merle, Philippe
    Meyer, Tim
    Qin, Shukui
    Ikeda, Masafumi
    Xu, Ruocai
    Edeline, Julien
    Ryoo, Baek-Yeol
    Ren, Zhenggang
    Cheng, Ann-Lii
    Galle, Peter R.
    Kaneko, Shuichi
    Kumada, Hiromitsu
    Wang, Anran
    Mody, Kalgi
    Dubrovsky, Leonid
    Siegel, Abby B.
    Llovet, Josep M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 482 - 482
  • [27] Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Abou-Alfa, Ghassan K.
    Blanc, Jean-Frederic
    Miles, Steven
    Ganten, Tom M.
    Trojan, Jorg
    Cebon, Jonathan S.
    Liem, Andre K. D.
    Lipton, Lara Rachel
    Gupta, Charu
    Wu, Benjamin
    Litten, Jason B.
    Saltz, Leonard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [28] RELATIVITY-106: A phase 1/2 trial of nivolumab (NIVO) plus relatlimab (RELA) in combination with bevacizumab (BEV) in first-line (1L) hepatocellular carcinoma (HCC).
    Sangro, Bruno
    Yau, Thomas
    Harding, James J.
    Rivera, Mirelis Acosta
    Kazushi, Numata
    El-Khoueiry, Anthony B.
    Cruz-Correa, Marcia
    Perez-Callejo, David
    McLean, Sean
    Sparks, Jacy
    Neely, Jaclyn
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS636 - TPS636
  • [29] EFFICACY AND TOLERABILITY OF BEVACIZUMAB (B) AND ERLOTINIB (E) AS FIRST-LINE THERAPY IN ASIAN PATIENTS (PTS) WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC): A PHASE II TRIAL
    Hsu, C.
    Kang, Y.
    Yang, T. S.
    Su, W.
    Shun, C.
    Sandoval-Tan, J.
    Chiou, T.
    Jin, K.
    Hsu, C.
    Cheng, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 237 - 237
  • [30] Updated results of a phase 1b study of regorafenib (REG) 80 mg/day or 120 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).
    El-Khoueiry, Anthony B.
    Kim, Richard D.
    Harris, William Proctor
    Sung, Max W.
    Waldschmidt, Dirk
    Cabrera, Roniel
    Garosi, Vittorio Luigi
    Zebger-Gong, Hong
    Brennan, Barbara J.
    Wang, Ying A.
    Mueller, Udo
    Ishida, Tatiane Cristine
    Galle, Peter R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345